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Control and prevention of foot and mouth disease (FMD) by vaccination remains unsatisfactory in endemic
countries. Indeed, consistent and new FMD epidemics in previously disease-free countries have precipitated the
need for a worldwide control strategy. Outbreaks in vaccinated animals require that a new and safe vaccine be
developed against foot and mouth virus (FMDV). FMDV can be eradicated worldwide based on previous scientific
information about its spread using existing and modern control strategies.
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Foot-and-mouth disease (FMD) is one of the most eco-
nomically and socially devastating diseases affecting
cloven-hoofed livestock worldwide. It is caused by a
highly variable RNA virus with seven serotypes (A, O, C,
Asia 1, SAT 1, SAT 2, and SAT 3) and a large number of
topotypes [1]. Millions of animals are sacrificed every year
worldwide under FMDV eradication programmes [2].
FMDV has continuously circulated ever since after the
first outbreak in America in 1870 [3,4]. Further, new sub-
types of FMDV are continuously evolving due to an infin-
ite mutation rate in the RNA genome of the virus [5].
Over the last few decades, disease-free countries have pri-
marily adopted the strategy of slaughtering carrier animals
combined with transport restrictions and other sanitary
measures. Additionally, rapid vaccination is applied to limit
the spread of infection in outbreak regions [6,7].
Currently, inactivated vaccines are used as a major tool
in FMD eradication programmes in Europe as well as
other parts of the world. However, these vaccines have a
number of limitations such as propagation of virulent
virus, threat of virus escape from manufacturing sites,
limited shelf-life, and booster injection requirement after
4–12 months [8]. Sterility, safety, cost-effectiveness, easy
delivery, and long-lasting immunity against multiple* Correspondence: mabnvl@gmail.com
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ventional inactivated vaccines [8].
Recently, transgenic vaccines were demonstrated as a
novel and safe strategy for the control and prevention of
FMD. Specifically, animal fodder-based edible transgenic
vaccines containing protein-expressing viral genomes are
feasible to immunize animals. Many studies have sug-
gested that FMD plant-derived edible vaccines will be-
come common within the next few years [9].Review
Continent disease spread
Control of FMD is difficult due to variations in viral
serotype and consistency, effectiveness of control mea-
sures, and emergence of new subtypes. FMD outbreaks
also originate from transportation of carrier animals to
susceptible populations or disease-free regions. More-
over, prevalence of FMD increases due to seasonal or
periodic cycling, host susceptibility, and predisposal to
epizootic risk [10]. There are still many gaps in our un-
derstanding of FMD, especially in Asian countries. Rapid
investigation of outbreaks samples and interpretation of
data are made possible due to recent development of
tools and techniques. Independent and collaborative
works by various national animal health services, key
control initiatives, laboratory networks, and many other
groups have improved our knowledge of FMD [10].
Many countries have obtained FMD-free status from
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merged in previously disease-free countries due to in-
creased viral escape from vaccinated animals and import
of animal products from FMDV-circulating countries.
Many countries have maintained their disease-free status
by strict monitoring and culling of infected animals
[11,12]. The southern part of South America achieved
FMD-free status from the OIE in the late 1990s with the
help of a strict eradication program, and other countries
such as Uruguay, Argentina, Paraguay, and Brazil
achieved FMD-free status via vaccination in 1994, 1997,
1997, and 1998, respectively [13].
Recently, FMD has reemerged in Japan and South
Korea. Japan first achieved FMD-free status without vac-
cination in 2000, and FMD O serotype has not been re-
ported in Mongolia and Russia since 2003 and 2004,
respectively. In 2010, FMD serotype A and O outbreaks
were reported in South Korea and Japan, respectively.
However, FMD A outbreak in South Korea was con-
trolled by March 2010 while the FMD O outbreak in
Japan was controlled by June 2010 [12]. FMD outbreaks
of serotype O continue to pose a threat to livestock in-
dustries in this region (Table 1) [14].Table 1 Countries with FMD free status in 2011 according
to OIE [12]
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France NetherlandsMajor causes of FMD spread in Asian/developing countries
Asian countries suffering from FMD outbreaks often lack
coordinated or serious mandatory measures for control of
this disease. Further, movement and exchange of animals
and animal products across neighboring countries are very
common. The amount of FMD vaccines produced locally
is insufficient to fulfill the demands of large populations of
animals in developing countries [5,15,16]. Moreover, FMD
outbreaks among vaccinated animals in this region may be
due to poor vaccine quality, lack of knowledge of circulat-
ing subtypes, and suboptimal vaccination strategies such
as single vaccine injection without any booster [15].
Virus distribution
Serotypes O, A, and Asia 1 are continuously circulating
in many FMD endemic countries in Asia, Europe, and as
well as Africa. Moreover, serotype C was reported in the
Philippines in 1995, whereas SAT 1, 2, and 3 are com-
mon in African countries. Recently, disease-reporting
transparency has improved due to increased field sur-
veillance, outbreak investigation, and submission of virus
samples for analysis by central reference laboratories
such as the World Reference Laboratory (WRL) and
FAO/OIE Reference Laboratory. However, efforts are
still insufficient for comprehensive control and complete
disease eradication [10,17].
Serotype O
FMDV serotype O is the predominant serotype of FMD
worldwide. It is the most prevalent serotype in many
parts of Africa, the Middle East such as Pakistan, and
some parts of Europe. However, an accurate genetic ex-
planation for the higher prevalence of O serotype is not
yet available [18,19]. Serotype O has been responsible
for severe disease outbreaks in Taiwan, Korea, Pakistan,
Iran, Afghanistan, Israel, China, North Korea, and Bulgaria
[17,20,21]. O1Manisa vaccine has been proven to be a ro-
bust immune dominant strain in many FMD O outbreaks,
but it still does not protect against all epidemics. More-
over, several other O serotype vaccines have been used to
improve vaccine efficacy for circulating outbreaks [10].
Serotype A
Members of this serotype show high antigenic diversity
and no cross-protection between strains [16,22-24].
Genetic recombination is more common in serotype A
than in other serotypes of FMD [25,26]. Serotype A is
prevalent in ruminant populations of Thailand and
Malaysia. The most recent outbreaks of serotype A were
reported in Pakistan, Turkey, Egypt, India, China, and
South Korea. Serotype A has been successfully con-
trolled and eradicated in South Korea [17]. Different
vaccines for serotypes A confer variable levels of protec-
tion. A Iran-05, A22 Iraq, and A24Cruzeiro serotypes
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A [10,17].
Serotype Asia 1
Serotype Asia 1 is the most antigenically stable serotype
and shows relatively low levels of antigenic variation, al-
though it is still capable of antigenic drift. Various histor-
ical epizootics have been reported mainly in Southeast
Asian countries. Recently, serotype Asia 1 was shown to
affect ruminants in China, Pakistan, Bahrain, Iran, Turkey,
and Afghanistan in a cyclical pattern [17]. The Asia 1/
Shamir immune dominant serotype has been proven to be
a very valuable serotype to control outbreaks in Asian
countries and is still recommended to address FMD Asia
1 outbreaks [17].
Serotypes SAT 1, 2, 3
SAT (Southern African Territories) serotypes are usually
found in Africa, but a few outbreaks were recorded in Saudi
Arabia and Kuwait in 2000 [27]. SAT have genetically more
diverse FMD serotypes than other regions [28]. SAT 1 was
reported in 2003, 2006, and 2009 in South Africa, whereas
SAT 2 as reported in South Africa, Botswana, and Tanzania
in 2008, 2010, and 2012 respectively. SAT 3 was last re-
ported in 2006 in South Africa [17].
Serotype C
Sporadic outbreaks of serotype C have been reported in
South America, East Africa, and Pakistan between 2000
and 2006 [29]. There have been no major epidemics in
the last 20 years of this serotype [29]. Use of serotype C
in vaccination may actually increase the risk of vaccine-
induced outbreaks [30].
FMDV genome and its role in infection
FMDV is an infectious RNA virus divided into three major
functional regions. It comprises a 5′ non-coding regula-
tory region, protein-coding (L/P1, P2, and P3) region, and
3′ non-coding regulatory region. The protein P1 coding
region encodes four structural capsid proteins, whereas
P2–P3 regions encode non-structural proteins for replica-
tion and viral maturation. The functions of the non-
structural proteins are still poorly understood [6,31].
Initiation of infection
FMDV infection is initiated by attachment of the RGD
loop of viral capsid protein (VP1) to host surface integ-
rins on target cells. This interaction between virion and
cells is altered in some cell cultures in which a selected
stretch of VP3 binds to heparin-like moieties on the
cell culture surface [32]. AVB3 (Alpha V Beta), AVB5,
and AVB6 integrins are virus attachment receptors in
cattle [33].Virus immune response and vaccines
Insufficient FMDV immunity can be attributed to the
epitope between amino acids 140 to 160 having affinity
for only B lymphocytes and not T lymphocytes. Identifi-
cation of T lymphocyte-stimulating epitopes is thus a re-
quirement for future vaccines. The three dimensional
structure of FMDV includes a G-H loop in VP1 [4]. This
G-H loop (highly conserved arginine-glycine-aspartic
acid sequence) participates in binding to cell receptors
[6,34,35]. Moreover, viruses containing a single point
mutation in the RGD segment of VP1 regain virulence
upon restoration of the RGD sequence [36]. However,
RGD-deleted vaccines perform similar/better than BEI-
inactivated ones with respect to protection against chal-
lenge and induction of immune response. Thus, an ef-
fective vaccine can be prepared by deletion of cell-
binding sites from the virus using a genetic engineering
approach [37].
Current major vaccines
Vaccination is a major approach for controlling the spread
of FMD. Inadequate safety and disease protection associ-
ated with conventional (inactivated or attenuated) vaccines
has precipitated the need to develop effective and safe
FMD vaccines. Adequate epidemiological data and revac-
cination times for different circulating serotypes are im-
portant for control of FMD in endemic regions [38].
Production of FMD vaccine requires large-scale antigen
propagation, viral treatment for loss of pathogenicity, and
adjuvant addition to enhance the immune response [39].
Good quality vaccines will allow avoidance of production
loss and incidence of FMD [40]. Oil adjuvant of the Mon-
tanide series appears to be a promising candidate for a new
generation of FMD vaccines [41]. Previously developed
FMD vaccines were mostly ineffective [8] (Tables 2 and 3).
Inactivated and attenuated vaccines
Inactivated vaccines are commonly used and effective
tools to address FMDV outbreaks, but their production
is expensive and is associated with risk of disease spread
[38]. Virus propagated on cell culture (BHK-21) and
chemically inactivated by binary ethyleneimine has been
shown to be an effective vaccination protocol. Vaccine
inactivated by aziridine and acetylethyleneimine and
mixed with adjuvant such as aluminum hydroxide or
saponin has been used at large scale due to its reliability
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vealed that vaccinated animals lack an immune response
to non-structural proteins (NSPs) from viruses. This
information can be used for serological screening of
infected and carrier animals during vaccination. The
manufacturers always face the problem of incomplete in-
activation of virus along with screening of vaccinated
and non-vaccinated animals [36,42].
Moreover, vaccine production against individual FMD
serotypes is very challenging using a virus inactivation
approach. Such vaccines may also lose potency and ef-
fectiveness from production to application due to errors
in the cold delivery chain and field-limiting serotypes or
topotypes. Further, short-lived immunity requires a
booster, and inability to eradicate virus from carrier ani-
mals presents some limitations related to inactivated
vaccines [34,43].
Recently, inactivated FMDV (iFMDV) vaccines (Cliptox-
TM) have been shown to produce a specific antibody re-
sponse in mucosal tissues and sera along with a Th1/Th2
response [44]. Previously, FMDV receptor or receptor-
binding site-deleted/replaced FMDV attenuated vaccine
has been explored for FMD protection in cattle [44,45].
Live attenuated vaccines prepared from leader proteinase-
deficient serotype A12 and capsid containing 3C proteinase
coding regions of Asia I/HNK/CHA/05 provide effective
protection to cattle from FMDV. These studies validate the
successful use of live/attenuated vaccine for FMD protec-
tion in endemic areas [46-48].
Peptide vaccine
Synthetic peptides are another promising technology for
the control of FMD. A single epitope such as the G-H
loop in the viral capsid and C-terminal region of VP1
correspond to B cell epitopes and stimulate an immune
response with limited disease protection [49,50]. In
addition, B cell affinity sites on VP1 as well as TH sitesoutside of VP1 are needed for production of neutralizing
antibodies with high affinity. A peptide vaccine with both
immunogenicity and antigenic cross-reactivity among se-
rotypes was successfully developed from the entire G-H
loop domain, flanking sequences (129–169), and artificial
TH site of FMDV serotype O [31,51]. Immunization with
peptides containing G-H loop either alone or in com-
bination with an independent T cell epitope has been
shown to induce 23% to 39% partial protection from
viral infection [31,36].
Partial or complete removal of the VP1 G-H loop is
a novel approach to develop FMDV negatively marked
vaccines [52]. Dendrimeric peptide vaccine specifically
induces high titers of FMDV-neutralizing antibodies and
activates an FMDV-specific T cell response in pigs. Ani-
mals immunized with peptide vaccine are protected
against specific FMDV challenge [53]. Peptide vaccines
have limitations such as incomplete protection due to a
limited number of antigenic sites that interact with the
immune system, discontinuous antigenic sites on VP1,
and the quasi species nature of the virus [51]. These lim-
itations of peptide vaccines allow for different FMDV
antigenic variants, resulting in outbreaks in vaccinated
animals. Future peptide vaccines should have advanced
and paramount viral structures to induce effective and
complete immune responses [54].
Recombinant protein of FMD
Recombinant proteins are an alternative immunization
method and are based on a set of effective epitopes
within a single polypeptide chain. B and T cell polyepi-
tope proteins can also be used to induce an effective im-
mune response [55]. In previous studies, FMD synthetic
polypeptides were shown to protect laboratory animals
such as mice, rabbits, and guinea pigs. However, there
is still no recombinant FMD vaccine commercially avail-
able for farm animals [56,57]. It has previously been
shown that empty FMDV capsids are capable of eliciting
the same antibody response as infectious FMDV particles
[58]. Recombinant vaccine from B cell epitopes of VP1
and VP4 as well as T cell epitopes of proteins 2C and 3D
was previously developed in E.coli or N. benthamiana
plants using a phytoviral expression system. Immunization
of guinea pigs with purified proteins has been shown to
induce an efficient immune response against FMDV
serotype O/Taiwan/99 as well as protection against hom-
ologous viral challenge [59]. Therefore, recombinant poly-
epitope viral proteins may be used as commercially
available vaccination tools for the control and prevention
of FMD in the future.
FMDV live vector vaccine
A promising novel FMD vaccination approach was devel-
oped using replication-defective human adenovirus serotype
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vectored vaccines with interferon or FMDV capsid pro-
teins co-expressed with viral protease for processing
have been shown to confer protection against FMD in
pigs and cattle [61]. Previously, an experimental vaccine
was also developed using replication-defective human
adenovirus serotype 5 (Ad5) containing transgenes from
FMDV P1 (coding for capsid proteins), NSP 2A, 2B,
nearly all 3B, and 3C protease [62]. In another study,
Ad5-A24-modified candidate also successfully protected
animals against challenge with homologous FMDV.
Similarly, FMD construct without 3D (polymerase) NSP
portion was used to successfully differentiate among
FMDV infected and vaccinated animals [63].
Pseudorabies virus-derived virus-like particles (VLPs)
are highly immunogenic and helpful for safe production
of FMD proteins in vaccinated animals [48]. Previously,
single vaccination with an empty capsid from FMDV
serotype Asia I/HNK/CHA/05 expressed by a silkworm
baculovirus expression vector protected 80% of cattle
from virulent homologous virus [64]. In the future,
adenovirus or other viral-associated recombinant vac-
cines may be successful commercial candidates for the
control and prevention of FMD.
Transgenic vaccine in plants
Transgenic vaccines in plants were first discussed by Mason
[65]. Such vaccines are now considered as a promising op-
tion for linear epitopes. Further, FMDV edible vaccines in
transgenic plants as bioreactors may overcome problems
with cold storage and transportation of inactivated vac-
cines [6,9,66,67]. Previously, VP1 structural proteins were
successfully expressed in Arabidopsis thaliana, alfalfa, and
potato plants [66,68]. Lower expression and detection of
transgenic proteins in plants are two major limitations to
the application of edible vaccines. Reporter β glucuroni-
dase gene was shown to facilitate rapid screening and
identification of a number of transgenic plants. The se-
lected plants developed strong and protective antibody re-
sponses against virulent FMDV in experimental hosts [9].
FMDV VP1 protein has been expressed in transgenic
plants, and successful immunization in mice was also re-
ported from China and Argentina [69,70].
Many studies have been conducted to develop FMD ed-
ible vaccines with an effective immune response in plants
such as tomato, Arabidopsis thaliana, potato, Chlamydo-
monas chloroplasts, and tobacco [59,65,71-75]. Tissue-
specific promoters increase FMD transgene expression at
specific locations such as seeds for a specific time period
in edible vaccines [1,65]. In a previous study, a novel oral
immunization system was successfully developed against
FMD using structural proteins (VP1) from serotypes O
and Asia 1 in maize, and both transgenes were stably
transmitted to the next generation [54]. Recombinantvaccines in transgenic plants such as cereals lack compli-
cations related to viral or prion adulteration in vaccines,
along with many other benefits. Production of recombin-
ant vaccines in plants is very economical and reduces
transportation and storage costs [76]. Moreover, direct
oral administration with multiple components makes ed-
ible vaccines more valuable [77]. Antigen expression in
transgenic plants is more useful for experimental and
commercial animal vaccine development as compared to
classical methodologies.
Conclusion
Control and eradication of FMD from endemic regions are
only possible by combined efforts of the international com-
munity to produce cost-effective and environmentally
friendly vaccines against circulating FMDV serotypes. Vac-
cination can be an effective control measure depending on
local epidemiological and scientific disease information.
The effectiveness of heterologous vaccination should also
be studied with respect to antigenic matching of circulating
serotypes with immediate selection of effective vaccines
during outbreaks. FMD vaccination strategies, vaccine pro-
duction, storage, and transportation are real practical chal-
lenges, especially in developing countries. In this scenario,
transgenic vaccines in plants are attractive alternatives to
conventional FMD vaccines. Plants can be grown effi-
ciently at large-scale and easily delivered. However, produc-
tion of FMD chimeric plant-based vaccines from local
isolates is a real challenge worldwide. Sequence analysis of
circulating virus is also very important for continuous as-
sessment of mutation and antigenic changes in the viral
genome. The vaccine should be improved with circulating
serotype in case of any genetic difference from the field iso-
late. Disease-free countries must pay special attention to
protect their livestock from FMD-infected animals and ani-
mal products. Modern transgenic vaccination can be used
to lower the risk of disease in FMD-free countries and can
help these countries to maintain their disease-free status.
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